141 related articles for article (PubMed ID: 35158044)
1. Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability.
Tian Y; Lahue BR; Ma Y; Nair LG; Pan W; Doll RJ; Guzi T; Ma Y; Wang Y; Bogen SL
Bioorg Med Chem Lett; 2022 Apr; 61():128625. PubMed ID: 35158044
[TBL] [Abstract][Full Text] [Related]
2. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
[TBL] [Abstract][Full Text] [Related]
3. Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
Pan W; Lahue BR; Ma Y; Nair LG; Shipps GW; Wang Y; Doll R; Bogen SL
Bioorg Med Chem Lett; 2014 Apr; 24(8):1983-6. PubMed ID: 24656661
[TBL] [Abstract][Full Text] [Related]
4. Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.
Azzarito V; Rowell P; Barnard A; Edwards TA; Macdonald A; Warriner SL; Wilson AJ
Chembiochem; 2016 Apr; 17(8):768-73. PubMed ID: 26690307
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Suppression of a Protein-Protein Interaction in Cells Using Small-Molecule Covalent Inhibitors Based on an
Ueda T; Tamura T; Kawano M; Shiono K; Hobor F; Wilson AJ; Hamachi I
J Am Chem Soc; 2021 Mar; 143(12):4766-4774. PubMed ID: 33733756
[TBL] [Abstract][Full Text] [Related]
7. Design of libraries targeting protein-protein interfaces.
Fry D; Huang KS; Di Lello P; Mohr P; Müller K; So SS; Harada T; Stahl M; Vu B; Mauser H
ChemMedChem; 2013 May; 8(5):726-32. PubMed ID: 23436619
[TBL] [Abstract][Full Text] [Related]
8. Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction.
Plante JP; Burnley T; Malkova B; Webb ME; Warriner SL; Edwards TA; Wilson AJ
Chem Commun (Camb); 2009 Sep; (34):5091-3. PubMed ID: 20448956
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.
Tian Y; Ma Y; Gibeau CR; Lahue BR; Shipps GW; Strickland C; Bogen SL
Bioorg Med Chem Lett; 2016 Jun; 26(11):2735-8. PubMed ID: 27080185
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
11. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
[TBL] [Abstract][Full Text] [Related]
12. Discovery of
Reutershan MH; Machacek MR; Altman MD; Bogen S; Cai M; Cammarano C; Chen D; Christopher M; Cryan J; Daublain P; Fradera X; Geda P; Goldenblatt P; Hill AD; Kemper RA; Kutilek V; Li C; Martinez M; McCoy M; Nair L; Pan W; Thompson CF; Scapin G; Shizuka M; Spatz ML; Steinhuebel D; Sun B; Voss ME; Wang X; Yang L; Yeh TC; Dussault I; Marshall CG; Trotter BW
J Med Chem; 2021 Nov; 64(21):16213-16241. PubMed ID: 34714078
[TBL] [Abstract][Full Text] [Related]
13. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
14. P53 mdm2 inhibitors.
Khoury K; Dömling A
Curr Pharm Des; 2012; 18(30):4668-78. PubMed ID: 22650254
[TBL] [Abstract][Full Text] [Related]
15. Small molecular weight protein-protein interaction antagonists: an insurmountable challenge?
Dömling A
Curr Opin Chem Biol; 2008 Jun; 12(3):281-91. PubMed ID: 18501203
[TBL] [Abstract][Full Text] [Related]
16. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
Parks DJ; LaFrance LV; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Schubert C; Koblish HK; Zhao S; Franks CF; Lattanze J; Carver TE; Cummings MD; Maguire D; Grasberger BL; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jun; 16(12):3310-4. PubMed ID: 16600594
[TBL] [Abstract][Full Text] [Related]
17. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
[TBL] [Abstract][Full Text] [Related]
19. Miniature protein inhibitors of the p53-hDM2 interaction.
Kritzer JA; Zutshi R; Cheah M; Ran FA; Webman R; Wongjirad TM; Schepartz A
Chembiochem; 2006 Jan; 7(1):29-31. PubMed ID: 16397877
[No Abstract] [Full Text] [Related]
20. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
